Frank Ruderman is the Executive Chairman of CardioRisk Laboratories. Prior to joining CardioRisk Laboratories, Mr. Ruderman was the President and CEO of Berkeley Heart Labs where he led the company to over $100MM in revenue from just over $1MM. Mr. Ruderman orchestrated the sale of Berkeley Heart Labs to Celera, a publically traded company, for $195MM. Mr. Ruderman had been a consultant and a director of Genomyx from its founding at Genentech with Human Genome Project funding, later acting as President/CEO and CFO. Genomyx was sold to Beckman Instruments. He founded and acted President, COO and a Director of Physiometrix, which went public at a $60MM valuation. Mr. Ruderman also helped to found two additional medical device companies, Intella Interventional (private) and Cardiac Pathways (public at a $200MM valuation) as spin-outs of Physiometrix. Mr. Ruderman served as a Board member, President, COO and CFO of American Bionetics, which saw revenue growth of 5x and its stock price increased to a high of 8x, the IPO price. The Company was sold to BioGenex after finalizing two acquisitions and completing joint ventures with Millipore and Dupont. He served as a member of the Board and the first President/CEO of Mast Immunosystems, which was sold to Hitachi. Before that, Mr. Ruderman served in various domestic and international corporate executive positions with Pfizer Pharmaceuticals, Pfizer Diagnostics and Millipore. Mr. Ruderman has an M.B.A. from the Amos Tuck School of Business at Dartmouth College, an M.A. in vascular physiology from Boston University, and a B.S. in biology from Tufts University.
Chief Executive Officer
Todd Eldredge currently serves as President and Chief Executive Officer at CardioRisk as well as a member of its board of directors. Todd directs all activities of the company with a focus on New Technology, Quality, and Marketing. Todd brings over 20 years of industry senior and executive management experience to the company. Most of this experience was within the pharmaceutical and other high-tech industries. Todd has served in executive management positions at STSN (iBaun), Document Control Systems (Master Control), Sanofi-Aventis and Rhone Poulenc. Prior to joining CardioRisk, Todd served as Vice President of Sales and Vice President / General Manager for a successful start-up that became the worldwide leader of services for business travelers. In this capacity he was actively engaged in growing their revenue from $1MM to over $100MM/year. He also served as Vice President of Sales and Marketing at Document Control Systems (now Master Control) an enterprise quality systems software solution for Fortune 1000 companies. Prior to DCS, Todd ran a business unit for Rhone-Poulenc, which was eventually purchased by Aventis (now Sanofi-Aventis), a publicly-traded company. Todd holds an MBA from Brigham Young University, an MPH, and a PhD in cardiovascular-epidemiology. He also the author of the #1 best selling book “Cardiovascular Wellness Management Success Plan”.
Vice President, Sales and Business Development
Prior to coming to CardioRisk Laboratories, Ken held multiple senior and executive management positions in publicly traded and large privately held companies whose revenues exceeded $350MM/year. Most recently he ran a successful business unit for Rhone-Poulenc. In this role he increased sales by over 300% in just under 3 years. He was also the US Director of Telesales for Sanofi Pastuer, and increased sales in this role by over 200% in two years while reducing expenses. Ken is an entrepreneur and started several companies including a successful Real Estate Management firm and more recently an Emergency Services Company where he had a successful exit which led to his retirement in 2013. In March of 2018, Ken received a CardioRisk Carotid artery Intima-Media Thickness (CIMT) exam and witnessed firsthand the lifesaving benefits of this technology. Weeks later he was persuaded out of a peaceful retirement to join the executive team at CardioRisk to help expand the usage of CIMT and help to make it a routine procedure in Primary Care. Ken directs the worldwide sales and business development efforts at CardioRisk.